B3GAT1 and prostate carcinoma: We found that genetically decreased levels of B3GAT1 (CD57; beta-1.3-glucoronyltransferase 1) are associated with increasing risk for prostate cancer (MR effect size = −0.080, MR p = 1.9 × 10−7).